The US Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab (Tecentriq, Genentech) for use in patients with metastatic non-small cell lung cancer (NSCLC) who have progressed during or after treatment with a platinum-based chemotherapy or appropriate targeted therapy, the manufacturer announced today.
Atezolizumab, a programmed cell death ligand-1 (PD-L1) inhibitor, was first approved in May for treatment of urothelial carcinoma. Researchers are currently testing the drug in patients with metastatic renal cell carcinoma or advanced melanoma.
The FDA determined that atezolizumab was safe and effective for treating NSCLC based on the phase III OAK and phase II POPLAR studies. In the OAK study, patients receiving atezolizumab lived a median 4.2 months longer than those treated with docetaxel chemotherapy.
More information on the FDA decision is available on the manufacturer's website.
Follow Robert Lowes on Twitter @LowesRobert
Medscape Medical News © WebMD, LLC
Heartwire © WebMD, LLC
WebMD Health News © WebMD, LLC
Reuters Health Information ©
Send comments and news tips to email@example.com.
Cite this: Tecentriq Approved for Metastatic Non-Small Cell Lung Cancer - Medscape - Oct 18, 2016.